Objective To investigate the effect and mechanism of dagliquin combined with liraglutide in the treatment of type 2 diabetes mellitus.Methods A total of 130 patients with type 2 diabetes admitted from May 2019 to May 2022 were selected as the research objects and divided into control group and observation group by random number table method,with 65 cases in each group.The control group was treated with liraglutide,and the observation group was treated with dagliquin combined with liraglutide.The therapeutic effects of the two groups were compared.Results After treatment,the mean blood glucose(MBG),standard deviation of blood glucose(SDBG)and postprandial glucose excursions(PPGE)in the observation group were lower than those in the control group(P<0.05).After treatment,the homeostasis model assessment-insulin resistance index(HOMA-IR)in the observation group was lower than that in the control group,and the homeostasis model assessment-β(HOMA-β)was higher than that in the control group(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α),plasminogen activator inhibitor-1(PAI-1)and cystatin C(CysC)in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of Nesfatin-1 and heat shock protein 60(HSP60)in the observation group were lower than those in the control group(P<0.05).Conclusion Dagliquin combined with liraglutide is beneficial to reduce blood glucose fluctuation and insulin resistance in patients with type 2 diabetes mellitus,and down-regulate the levels of TNF-α,PAI-1,CysC,Nesfatin-1 and HSP60,which is worthy of promotion.
维普
万方数据